BioMarin Pharmaceuticals BMRN Accretion (Amortization) of Discounts and Premiums, Investments
Accretion (Amortization) of Discounts and Premiums, Investments at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.
The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioMarin Pharmaceuticals's accretion (amortization) of discounts and premiums, investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is BioMarin Pharmaceuticals's accretion (amortization) of discounts and premiums, investments?
- BioMarin Pharmaceuticals (BMRN) reported accretion (amortization) of discounts and premiums, investments of $455K in Q1 2026.
- How has BioMarin Pharmaceuticals's accretion (amortization) of discounts and premiums, investments changed year-over-year?
- BioMarin Pharmaceuticals's accretion (amortization) of discounts and premiums, investments decreased by 66.6% year-over-year, from $1.36M to $455K.